Who Paid My Doc
Noumia Cloutier-Gill
Optometrist, Corneal and Contact Management Bloomington, MN Doctor of Optometry
NPI 1457508988 CMS profile 490255
9801 Dupont Ave S, Suite 425, Bloomington, MN 55431
General payments
$36
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Noumia Cloutier-Gill of Bloomington, MN is reported in the CMS Open Payments database as having received $36 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 5th percentile of Optometrist, Corneal and Contact Management profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $20 | 1 | |
| 2023 | General | $16 | 1 |
Beside peers
- Noumia Cloutier-Gill
- Optometrist, Corneal and Contact Management median
- Middle half of Optometrist, Corneal and Contact Management
- National median
In program year 2025, general payments to Noumia Cloutier-Gill were reported at $0. Among 618 Optometrist, Corneal and Contact Management profiles paid that year, the median was $227 and the middle half received between $95 and $604.
Show as a table
| Year | Noumia Cloutier-Gill | Optometrist, Corneal and Contact Management median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $203 | $84–$530 | $163 |
| 2020 | $0 | $88 | $35–$234 | $114 |
| 2021 | $0 | $143 | $54–$353 | $132 |
| 2022 | $0 | $167 | $65–$422 | $149 |
| 2023 | $16 | $195 | $76–$549 | $160 |
| 2024 | $20 | $202 | $85–$523 | $164 |
| 2025 | $0 | $227 | $95–$604 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 22 drugsPart D claims
1,067
Drug cost
$260,922
Branded share of claims
36.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Restasis Cyclosporine | Brand | 91 | $127,839 | |
| Xiidra Lifitegrast | Brand | 26 | $38,405 | |
| Cyclosporine | Generic | 59 | $32,325 | |
| Lumigan Bimatoprost | Brand | 44 | $22,648 | |
| Loteprednol Etabonate | Generic | 41 | $7,106 | |
| Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol | Brand | 17 | $4,887 | |
| Vyzulta Latanoprostene Bunod | Brand | 14 | $4,269 | |
| Fluorometholone | Generic | 53 | $3,786 | |
| Travoprost | Generic | 27 | $3,498 | |
| Latanoprost | Generic | 174 | $3,399 |
The 10 drugs with the highest cost, of 22 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 22 billing codesPaid by Medicare
$42,050
Medicare patients
297
Services billed
718
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 57% | |
| Arthritis | 40% | |
| Diabetes | 18% | |
| Ischemic heart disease | 17% | |
| Chronic kidney disease | 17% | |
| Depression | 16% | |
| Osteoporosis | 16% | |
| Cancer | 14% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Optometrist, Corneal and Contact Management in Minnesota
Ahmad Fahmy
Optometrist, Corneal and Contact Management · Minneapolis, MN
Scott Hauswirth
Optometrist, Corneal and Contact Management · Bloomington, MN
Mark Buboltz
Optometrist, Corneal and Contact Management · Bloomington, MN
Tina McCarty
Optometrist, Corneal and Contact Management · Fridley, MN
Thomas Elton
Optometrist, Corneal and Contact Management · Edina, MN
Alicia Alvarado
Optometrist, Corneal and Contact Management · Fridley, MN
Related records
Optometrist, Corneal and Contact Management in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Optometrist, Corneal and Contact Management
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.